Clinical resistance shortens survival for acute myeloid leukemia (AML) patients treated with targeted inhibitors. Resistance mechanisms to AML targeted therapies, including inhibitors of FLT3, BCL2 and IDH1/2, often converge upon the RAS/MAPK signaling pathway....
BackgroundAcute myeloid leukemia (AML) is a heterogeneous disease and is primarily defined by genetic abnormalities. Although accumulating evidence suggests the role of epigenetics in the pathogenesis of AML, it has not fully been investigated in a large cohort of...
Aneuploidy is common in solid tumors but only comprises ~10% of acute myeloid leukemias (AML), defined by complex karyotype (AML-CK) and associated with TP53 mutations and 5q loss. The drivers and trajectories of AML-CK evolution have not been experimentally...
Cofactors, many of which are vitamin-derived, are organic molecules with diverse biological functions. They are required for many metabolic pathways and enzymatic reactions, and thus can influence cell proliferation and differentiation. Though the role of vitamins in...
BackgroundIn 2022, the European LeukemiaNet (ELN) updated its guidelines for risk allocation in acute myeloid leukemia (AML) patients (Döhner H et al., Blood 2022). Subsequently, a few studies validated externally the prognostic value of this new classification in...
Recent Comments